Embed Size (px)
Citation preview
One-of-a-kind
research network.
Jointly funded by:
ECMC Programme Office
Aims of the Experimental Cancer Medicine Network
ECMC vision: to build a truly collaborative, internationally competitive national
network of early phase experimental cancer medicine centres, translating the
most promising innovations from the academic and industry sectors into the
cancer medicines of tomorrow
Delivering innovative
treatment for people
with cancer
Making the UK the
place of choice to
deliver trials
Building the capacity
of the Network
The ECMC Network: 3rd Quinquennium (2017-2022)
Funding
• >£7m p.a. provided by Cancer Research UK &
the Health departments of the devolved nations
• Funding committed until 2022
One Network
• Adult ECMC – 18 locations
• Paediatric ECMC – 11 locations
Each ECMC location has
• A university
• At least one NHS Health Trust/Board
• Each ECMC focuses on their local strengths in
disease type and treatment modality
Where we fit in the cancer research pathway
Core areas of ECMC activity
Preclinical Phase I Phase II Phase IIIDiscovery
Laboratory Trials and biomarkers Biomarkers
Basic Science
To build a framework that ensures every child in the
UK has equitable access to novel treatments.
To increase the attractiveness of the UK as a site for Early Phase trial
work
To provide the infrastructure to aid the UK to operate in international
precision medicine initiatives
To create a path for translational research to move from lab to clinic
To create a co-ordinated, co-operative network
ECMC Paediatric network 2017-22 11 centres funded by CRUK, NIHR and CSO
Core capabilities of the ECMC network
The ECMC Network provides
• Access to a large and diverse UK patient
demographic
• Access to key opinion leaders
• Proficiency in clinical & translational research
• Integration with the NHS
• Dedicated posts to support early phase trials and
translational research
• A network focused on delivery
The ECMC Programme Office provides
• A dedicated network access point for
industry
• Access to key opinion leaders
• Expedited study set up process
• A partnering model for combination studies
• Professional development & support for
the Network
• Site level intelligence
We provide the following support to industry:
Assisting industry in accessing the network
ECMC
NDA
EoI
Feasibility
Site
Selection
Support
Our Industry Engagement Process
5 days
5 days
5 days
Access to the network
Troubleshoot study start up
Clinical expertise (KoLs)
Feasibility site selection /
identification
Study / protocol development
Set-up
trouble shooting
Site level
intelligence
15 working
days
turnaround
Funder-sponsor breakdown of ECMC
supported treatment intervention trials
2007-2016
Over 25%academic
sponsored/other
funding
Over 60%industry
sponsored &
funded
Over 10%academic
sponsored/
industry funded
Active* phase 0 – II treatment intervention trials
*Active: in set-up, open, in follow-up and any trial that has since closed but has recruited/treated patients during the year
Working with industry
Industry case studies
• 7 x CTIMPs (Phase II)
• Online search – completed ‘Industry
Engagement Form’. Looking to include
additional sites to established pre-selected
sites
• Unmodified ECMC NDA used – fully
executed across network within 4 days
• Successfully facilitated EoI call for 2 studies
across network with sites identified and
selected
• Benefited from technical assurance reviews
as part of ongoing support for ECMC
locations by the HRA
BMS
• Biologics work programme (Phase I/II)
• Introduced by ECMC Lead – sponsor
looking to identify additional ECMC sites
and expertise
• Unmodified ECMC NDA used – fully
executed across network within 3 days
• Facilitated EoI call across network with 11
sites expressing initial interest
• In collaboration with CRO, 4 ECMC sites
selected with Oxford lead site
• Currently in start up
CytomX
The Combinations
Alliance
CURRENT PORTFOLIO:
5TRIALS IN SET UP
10PARTNERS
10RECRUITING
3CLOSE DOWN
+ =
•
•
•
•
•
•
•
Radiotherapy-Drug Combinations Consortium (RaDCom)
• Providing necessary preclinical evidence for early phase clinical trials
• Collaborative network of labs
• Partnership with industry, CRUK and other funding bodies
• Timely delivery of quality preclinical efficacy data
• Key point for industrial partners seeking appropriate expertise
Steering group
http://ctrad.ncri.org.uk/research-support/radiation-drug-combinations-radcom
Contact us
Programme Office
W: www.ecmcnetwork.org.uk
Combinations Alliance
W: www.ecmcnetwork.org.uk/ca
